Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2024 Jul 1;109(7):2331-2336.
doi: 10.3324/haematol.2023.284635.

Health-related quality of life in relapsed/refractory multiple myeloma treated with melflufen and dexamethasone: analyses from the phase III OCEAN study

Fredrik H Schjesvold  1 , Heinz Ludwig  2 , Sossana Delimpasi  3 , Pawel Robak  4 , Daniel Coriu  5 , Waldemar Tomczak  6 , Ludek Pour  7 , Ivan Spicka  8 , Meletios-Athanasios Dimopoulos  9 , Tamas Masszi  10 , Natalia G Chernova  11 , Anna Sandberg  12 , Marcus Thuresson  12 , Stefan Norin  12 , Nicolaas A Bakker  12 , Maria-Victoria Mateos  13 , Paul G Richardson  14 , Pieter Sonneveld  15
Affiliations
Clinical Trial

Health-related quality of life in relapsed/refractory multiple myeloma treated with melflufen and dexamethasone: analyses from the phase III OCEAN study

Fredrik H Schjesvold et al. Haematologica. .
No abstract available

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Mean scores at baseline through cycle 6 of treatment with melflufen plus dexamethasone or pomalidomide plus dexamethasone. C: cycle; D: day; dex: dexamethasone; melflufen: melphalan flufenamide; QoL: quality of life; VAS: visual analog scale.
Figure 2.
Figure 2.
Proportion of patients with improved, stable, or worsened patient-reported outcome measures at cycle 6. An improvement or worsening of an outcome was defined as a change of ≥10 points. QoL: quality of life; melflufen: melphalan flufenamide.
See this image and copyright information in PMC

References

    1. LeBlanc MR, Hirschey R, Leak Bryant A, LeBlanc TW, Smith SK. How are patient-reported outcomes and symptoms being measured in adults with relapsed/refractory multiple myeloma? A systematic review. Qual Life Res. 2020;29(6):1419-1431. - PMC - PubMed
    1. Engelhardt M, Ihorst G, Singh M, et al. . Real-world evaluation of health-related quality of life in patients with multiple myeloma from Germany. Clin Lymphoma Myeloma Leuk. 2021;21(2):e160-e175. - PubMed
    1. Richardson PG, Oriol A, Larocca A, et al. . Melflufen and dexamethasone in heavily pretreated relapsed and refractory multiple myeloma. J Clin Oncol. 2021;39(7):757-767. - PMC - PubMed
    1. Schjesvold FH, Dimopoulos MA, Delimpasi S, et al. . Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): a randomised, head-to-head, open-label, phase 3 study. Lancet Haematol. 2022;9(2):e98-e110. - PubMed
    1. Sonneveld P, Richardson PG, Ludwig H, et al. . Benefit versus risk assessment of melflufen and dexamethasone in relapsed/ refractory multiple myeloma: analyses from longer follow-up of the OCEAN and HORIZON studies. Clin Lymphoma Myeloma Leuk. 2023;23(9):P687-696. - PubMed

Publication types

MeSH terms

Associated data